TScan Therapeutics director awarded 67,000 stock options
TScan Therapeutics director Gabriela Gruia received a grant of stock options as part of her compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
TScan Therapeutics director Gabriela Gruia received a grant of stock options as part of her compensation. The award covers 67,000 options to buy Voting Common Stock at an exercise price of $0.9946 per share and expires on May 20, 2036.
According to the terms, these options will vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, provided she continues in service through that date. This filing reflects an equity grant, not an open‑market purchase or sale of shares.
Insider Trade Summary
Grant/Award: 67,000 shares
Grant/Award
1 txn
Insider
Gruia Gabriela
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 67,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 67,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
Key Figures
Options granted: 67,000 options
Exercise price: $0.9946 per share
Underlying shares: 67,000 shares
+3 more
6 metrics
Options granted
67,000 options
Stock Option (Right to Buy) awarded to director
Exercise price
<money>$0.9946</money> per share
Exercise price for Voting Common Stock under option
Underlying shares
67,000 shares
Voting Common Stock underlying granted options
Post-grant option holdings
67,000 options
Total derivative securities following this transaction
Vesting date trigger
<date>May 20, 2027</date>
Latest vesting date, or earlier at next annual meeting
Expiration date
<date>May 20, 2036</date>
Option expiration for this grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 0.9946"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-05-20T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TScan Therapeutics (TCRX) disclose in this Form 4 filing?
TScan Therapeutics reported that director Gabriela Gruia received a grant of 67,000 stock options. These options are part of her compensation package and give her the right to buy Voting Common Stock at a fixed exercise price if vesting conditions are met.
How many stock options did Gabriela Gruia receive from TScan Therapeutics (TCRX)?
Gabriela Gruia was granted 67,000 stock options. Each option relates to one share of Voting Common Stock, giving her the potential to purchase 67,000 shares if she exercises all options after they vest and before they expire.
What is the exercise price of the TScan Therapeutics (TCRX) stock options granted?
The stock options granted to Gabriela Gruia have an exercise price of $0.9946 per share. This means she can buy shares at that price once the options vest and before they expire, regardless of the market price at that time.
When do Gabriela Gruia’s TScan Therapeutics (TCRX) options vest?
The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders. Vesting is conditional on her continued service with TScan Therapeutics through the applicable vesting date.
When do the TScan Therapeutics (TCRX) options granted to Gabriela Gruia expire?
These options expire on May 20, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Voting Common Stock from TScan Therapeutics under this grant.
Does this TScan Therapeutics (TCRX) Form 4 show any stock being bought or sold on the market?
No, the Form 4 reports a grant of stock options, not an open-market trade. It reflects a compensation-related award giving future purchase rights, rather than an immediate purchase or sale of TScan Therapeutics shares in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates